

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1625
COLLINGWOOD, STEPHEN PAUL ET AL. EXAMINER: CHANG, CELIA C
INTERNATIONAL APPLICATION NO: PCT/EP2004/006795
FILED: JUNE 23, 2004
U.S. APPLICATION NO: 10/561366
35 USC §371 DATE: MAY 15, 2006
FOR: PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS
FOR THE MUSCARINIC M3 RECEPTOR

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

/Cozette M. McAvoy/

Cozette M. McAvoy
Attorney for Applicant
Reg. No. 60,457

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9273
Date: May 26, 2010